-
Je něco špatně v tomto záznamu ?
Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension
R. Channick, S. Medrek, M. Delcroix, S. Gaine, P. Jansa, I. Lang, V. McLaughlin, S. Mehta, T. Pulido, B. Sastry, R. Souza, A. Torbicki, C. Zhao, P. Strachan, P. Agron, J. Yen, O. Sitbon
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS: Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIPHON; NCT01106014) versus placebo (primary endpoint: time to morbidity/mortality [M/M]). This analysis defined age thresholds differentiating M/M risk in patients randomized to placebo (Cox regression determining treatment effect by age). RESULTS: Three age groups (< 35, 35-64, ≥ 65 years) showed good M/M risk discrimination (c-statistic 0.69, SERAPHIN; 0.66, GRIPHON). M/M risk was higher in placebo patients < 35 versus 35-64 years (SERAPHIN: hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.10-2.72, p = 0.02; GRIPHON: HR 1.81, 95% CI 1.28-2.56, p < 0.001). M/M risk trended higher in patients ≥ 65 versus 35-64 years (SERAPHIN: HR 1.55, 95% CI 0.89-2.69, p = 0.12; GRIPHON (HR 1.08, 95% CI 0.75-1.55, p = 0.69). M/M risk was lower with macitentan/selexipag versus placebo: macitentan < 35 (HR 0.44, 95% CI 0.25-0.78; p = 0.005), 35-64 (HR 0.50, 95% CI 0.33-0.76; p < 0.001), ≥ 65 years (HR 0.69, 95% CI 0.30-1.58; p = 0.38); selexipag < 35 (HR 0.50, 95% CI 0.32-0.78; p = 0.002), 35-64 (HR 0.72, 95% CI 0.54-0.96; p = 0.03), ≥ 65 years (HR 0.55, 95% CI 0.33-0.91; p = 0.02). Adverse-event discontinuations were similar. CONCLUSIONS: The benefit (vs placebo) of macitentan/selexipag on reducing risk of M/M events was consistent across all ages, including the younger group where significant treatment effects were observed.
Actelion Pharmaceuticals US Inc Titusville NJ
CARE Hospitals Hyderabad India
Centre of Postgraduate Medical Education European Health Centre ECZ Otwock Poland
Clinical Research Department National Heart Institute Mexico City Mexico
David Geffen School of Medicine at University of California Los Angeles Los Angeles CA
InCor Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo São Paulo Brazil
Janssen Research and Development LLC Raritan NJ
National Pulmonary Hypertension Unit Mater Misericordiae University Hospital Dublin Ireland
Université Paris Saclay APHP Hôpital Bicêtre Le Kremlin Bicêtre France
University Hospitals of Leuven Leuven Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25008493
- 003
- CZ-PrNML
- 005
- 20250422095831.0
- 007
- ta
- 008
- 250408e20250116xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jhlto.2024.100197 $2 doi
- 035 __
- $a (PubMed)40144855
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Channick, Richard $u David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
- 245 10
- $a Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension / $c R. Channick, S. Medrek, M. Delcroix, S. Gaine, P. Jansa, I. Lang, V. McLaughlin, S. Mehta, T. Pulido, B. Sastry, R. Souza, A. Torbicki, C. Zhao, P. Strachan, P. Agron, J. Yen, O. Sitbon
- 520 9_
- $a BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS: Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIPHON; NCT01106014) versus placebo (primary endpoint: time to morbidity/mortality [M/M]). This analysis defined age thresholds differentiating M/M risk in patients randomized to placebo (Cox regression determining treatment effect by age). RESULTS: Three age groups (< 35, 35-64, ≥ 65 years) showed good M/M risk discrimination (c-statistic 0.69, SERAPHIN; 0.66, GRIPHON). M/M risk was higher in placebo patients < 35 versus 35-64 years (SERAPHIN: hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.10-2.72, p = 0.02; GRIPHON: HR 1.81, 95% CI 1.28-2.56, p < 0.001). M/M risk trended higher in patients ≥ 65 versus 35-64 years (SERAPHIN: HR 1.55, 95% CI 0.89-2.69, p = 0.12; GRIPHON (HR 1.08, 95% CI 0.75-1.55, p = 0.69). M/M risk was lower with macitentan/selexipag versus placebo: macitentan < 35 (HR 0.44, 95% CI 0.25-0.78; p = 0.005), 35-64 (HR 0.50, 95% CI 0.33-0.76; p < 0.001), ≥ 65 years (HR 0.69, 95% CI 0.30-1.58; p = 0.38); selexipag < 35 (HR 0.50, 95% CI 0.32-0.78; p = 0.002), 35-64 (HR 0.72, 95% CI 0.54-0.96; p = 0.03), ≥ 65 years (HR 0.55, 95% CI 0.33-0.91; p = 0.02). Adverse-event discontinuations were similar. CONCLUSIONS: The benefit (vs placebo) of macitentan/selexipag on reducing risk of M/M events was consistent across all ages, including the younger group where significant treatment effects were observed.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Medrek, Sarah $u University of New Mexico, Albuquerque, NM
- 700 1_
- $a Delcroix, Marion $u University Hospitals of Leuven, Leuven, Belgium
- 700 1_
- $a Gaine, Sean $u National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland
- 700 1_
- $a Jansa, Pavel $u Second Department of Internal Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
- 700 1_
- $a Lang, Irene $u Department of Internal Medicine II, Cardiology and Center of Cardiovascular Medicine, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria
- 700 1_
- $a McLaughlin, Vallerie $u University of Michigan, Ann Arbor, MI
- 700 1_
- $a Mehta, Sanjay $u Respirology Division, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
- 700 1_
- $a Pulido, Tomas $u Clinical Research Department, National Heart Institute, Mexico City, Mexico
- 700 1_
- $a Sastry, Bhagavatula $u CARE Hospitals, Hyderabad, India
- 700 1_
- $a Souza, Rogerio $u InCor, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
- 700 1_
- $a Torbicki, Adam $u Centre of Postgraduate Medical Education, European Health Centre, ECZ-Otwock, Poland
- 700 1_
- $a Zhao, Carol $u Actelion Pharmaceuticals US, Inc., (a Johnson & Johnson Company), Titusville, NJ
- 700 1_
- $a Strachan, Paul $u Actelion Pharmaceuticals US, Inc., (a Johnson & Johnson Company), Titusville, NJ
- 700 1_
- $a Agron, Peter $u Janssen Research and Development, LLC, Raritan, NJ
- 700 1_
- $a Yen, Joseph $u Actelion Pharmaceuticals US, Inc., (a Johnson & Johnson Company), Titusville, NJ
- 700 1_
- $a Sitbon, Olivier $u Université Paris-Saclay, APHP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- 773 0_
- $w MED00216308 $t JHLT open $x 2950-1334 $g Roč. 7 (20250116), s. 100197
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40144855 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250408 $b ABA008
- 991 __
- $a 20250422095833 $b ABA008
- 999 __
- $a ok $b bmc $g 2306393 $s 1245568
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2025 $b 7 $c - $d 100197 $e 20250116 $i 2950-1334 $m JHLT open $n JHLT Open $x MED00216308
- LZP __
- $a Pubmed-20250408
